Enhanced IL-6 and IL-12B Gene Expression After SARS-CoV-2 Infection in Leprosy Patients May Increase the Risk of Neural Damage

Am J Trop Med Hyg. 2021 Apr 5;104(6):2190-2194. doi: 10.4269/ajtmh.21-0034.

Abstract

Experts have called attention to the possible negative impact of the coronavirus disease 2019 (COVID-19)-related cytokine storm syndrome on the progression of leprosy-related disabilities. We assessed the frequency of reactional states in patients co-infected with Mycobacterium leprae and severe acute respiratory syndrome (SARS) coronavirus (CoV) 2 (SARS-CoV-2). We consecutively included patients during the first peak of the COVID-19 epidemic in Brazil and analyzed the expressions of genes encoding interleukin (IL)-1β, IL-6, IL-8, IL-10, IL-12A, IL-12B, and tumor necrosis factor-α in peripheral blood mononuclear cells. We included 64 leprosy patients and 50 controls. Twelve of the leprosy patients and 14 of the controls had been diagnosed with COVID-19. Co-infection was associated with increased IL-6 (P = 0.043) and IL-12B (P = 0.017) expression. The median disability grades were higher for leprosy/COVID-19 patients; however, the difference was not significant (P = 0.194). Patients co-infected with M. leprae and SARS-CoV-2 may experience a higher-grade proinflammatory state.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • COVID-19 / complications
  • COVID-19 / immunology*
  • COVID-19 / metabolism
  • Cross-Sectional Studies
  • Female
  • Gene Expression Regulation / immunology
  • Humans
  • Interleukin-12 / genetics
  • Interleukin-12 / metabolism*
  • Interleukin-6 / genetics
  • Interleukin-6 / metabolism*
  • Leprosy / complications*
  • Male
  • Middle Aged
  • Peripheral Nerve Injuries / etiology*
  • Peripheral Nerve Injuries / metabolism
  • Peripheral Nerve Injuries / pathology

Substances

  • Interleukin-6
  • Interleukin-12